Latest news with #SanofiSA
Yahoo
02-06-2025
- Business
- Yahoo
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings significantly surpassed the company's expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release. Pharmacokinetics (PK): KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorption was demonstrated with a median tmax of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing, and a steady state was achieved by Day (PD): KT-621 demonstrated rapid, deep, and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621. STAT6 levels in blood and skin were measured. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or, when most subjects' STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both. In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching >90% across all SAD doses starting at 6.25 mg. All SAD cohorts at 75 mg or greater doses achieved >95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects. In MAD, STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg. Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg, with recovery starting as early as 4 days after the last dose. In MAD, robust STAT6 degradation was observed in the skin at the first timepoint measured (Day 7) for doses above 1.5 mg. Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg. Th2 Biomarkers: TARC reduction was observed for all KT-621 dose groups, with a median reduction of up to 37% at Day 14. The company says the results are comparable or superior to what was seen in the Sanofi SA (NASDAQ:SNY)/Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) Dupixent (dupilumab) healthy volunteer study. The safety profile of KT-621 was undifferentiated from that of the placebo. The company's KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is ongoing, with data expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b trials in atopic dermatitis and asthma will start in 4Q25 and 1Q26, respectively. Price Action: KYMR stock was trading higher by 30.2% to $38.58 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Hindustan Times
02-06-2025
- Business
- Hindustan Times
Sanofi to buy US biopharma group Blueprint Medicines for $9.1 Billion equity value
Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical firm expand its rare immunological disease portfolio. Sanofi will pay $129 per share in cash, the companies said in a statement Monday. That represents a 27% premium to Blueprint's closing price on Friday. Blueprint shareholders will also receive one non-tradeable contingent value right, which will pay the holder $2 and $4 per right for the achievement, respectively, of future development and regulatory milestones for BLU-808 — a potential treatment for patients with mast cell disorders, including chronic urticaria. Including the potential CVR payments, the deal amounts to about $9.5 billion on a fully diluted basis. Sanofi expects to complete the acquisition in the third quarter and said the deal won't have a significant impact on its financial guidance for 2025.
Yahoo
15-05-2025
- Business
- Yahoo
Acthib, Omnihib Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F
The key company operating in the acthib, omnihib market is Sanofi SA. North America was the largest region in the acthib, omnihib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acthib, omnihib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acthib, omnihib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Acthib, Omnihib Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Acthib, Omnihib market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. ActHIB and OmniHIB are vaccines designed to protect against invasive diseases caused by Haemophilus influenzae type b (Hib), including conditions such as meningitis and pneumonia. ActHIB is a conjugate vaccine, which combines the Hib capsular polysaccharide with a protein, while OmniHIB is a similar conjugate vaccine. Both vaccines are primarily given to infants and children to help build immunity. They play a vital role in preventing Hib-related illnesses, which can be severe or acthib, omnihib market consists of sales of Hib vaccines, boosters, and pediatric vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the growth during the historical period can be attributed to the expansion of global immunization programs, increased pediatric vaccination rates, a surge in Hib disease outbreaks, higher adoption of combination vaccines, and growing public awareness of vaccine-preventable diseases. Market growth during the forecast period is driven by increasing awareness and efforts to control Hib infections, a rise in the incidence of Hib-related infections, expanding immunization rates, greater use of antibiotics and glucocorticoids, and the rising prevalence of chronic diseases. Key trends during the forecast period include advancements in pediatric vaccination, improvements in vaccine technology, innovation and new product developments, and progress in vaccine delivery growing prevalence of Haemophilus influenzae type b (Hib) infections is expected to drive the growth of the ActHIB and OmniHIB market. Haemophilus influenzae type b infections are serious bacterial infections caused by the Haemophilus influenzae type b bacteria, which can lead to conditions such as meningitis, pneumonia, and epiglottitis, primarily affecting young children. The rise in Hib infections can be attributed to factors such as declining vaccination rates, the emergence of antibiotic resistance, and limited access to healthcare in certain regions. ActHIB and OmniHIB vaccines are designed to protect against Hib infections by stimulating the immune system to recognize and combat the bacteria. For example, a report from the European Centre for Disease Prevention and Control (ECDC) in July 2024 noted a significant increase in confirmed cases of invasive Haemophilus influenzae disease, with 3,967 cases reported in 2022, a sharp rise from 1,694 cases in 2021. This increasing prevalence of Hib infections is driving the demand for ActHIB and OmniHIB rise in healthcare expenditure is expected to support the growth of the ActHIB and OmniHIB market. Healthcare expenditure refers to the total spending on healthcare services, including personal care, preventive services, and public health activities aimed at improving health outcomes. This expenditure is increasing due to factors such as an aging population, rising chronic diseases, advanced medical technology, high drug costs, and inefficiencies in payment models, along with a growing demand for healthcare services. As healthcare spending increases, it can enhance the accessibility and affordability of vaccines such as ActHIB and OmniHIB, thereby influencing vaccination rates and public health outcomes. For instance, in May 2024, the Office for National Statistics in the UK reported a 5.6% rise in total healthcare expenditure from 2022 to 2023, compared to a growth rate of just 0.9% the previous year. Additionally, long-term health and social care expenditure grew by 2.8% in real terms in 2022. As a result, rising healthcare expenditure is contributing to the growth of the ActHIB and OmniHIB in biopharmaceutical solutions are another key factor driving growth in the ActHIB and OmniHIB market. A significant trend is the development of innovative combination vaccines that provide broader protection against multiple diseases while reducing the number of shots needed for immunization. A conjugate vaccine, which combines a bacterial polysaccharide with a protein to boost the immune response, is an example of such an Topics Covered: 1. Executive Summary2. Acthib, Omnihib Market Characteristics3. Acthib, Omnihib Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Acthib, Omnihib Market Trends and Strategies5. Acthib, Omnihib Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Acthib, Omnihib Growth Analysis and Strategic Analysis Framework6.1. Global Acthib, Omnihib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Acthib, Omnihib Market Growth Rate Analysis6.4. Global Acthib, Omnihib Historic Market Size and Growth, 2019-2024, Value ($ Million)6.5. Global Acthib, Omnihib Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)6.6. Global Acthib, Omnihib Total Addressable Market (TAM)7. Global Acthib, Omnihib Pricing Analysis & Forecasts8. Acthib, Omnihib Market Segmentation8.1. Global Acthib, Omnihib Market, Segmentation by Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Monovalent Hib Vaccines Combination Vaccines 8.2. Global Acthib, Omnihib Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Haemophilus Influenzae Type B (HIB) Infection 8.3. Global Acthib, Omnihib Market, Segmentation by Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Infants and Toddlers Adults 8.4. Global Acthib, Omnihib Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Hospitals and Clinics Retail Pharmacies 9. Global Acthib, Omnihib Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Acthib, Omnihib Market Regional and Country Analysis10.1. Global Acthib, Omnihib Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million10.2. Global Acthib, Omnihib Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
14-05-2025
- Business
- Bloomberg
Sanofi to Invest at Least $20 Billion in US Through 2030
Sanofi SA said it will invest at least $20 billion in the US through 2030, joining other European pharmaceutical companies boosting their American operations as President Donald Trump threatens to impose tariffs and cut prices on drugs. The investments will include a 'significant increase' in research and development spending and billions of dollars devoted to US manufacturing, Sanofi said in a statement Wednesday.
Yahoo
02-05-2025
- Business
- Yahoo
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and Symbicort pressurized metered-dose inhaler (pMDI). KALOS and LOGOS included approximately 4,400 randomized trials met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. No new safety or tolerability signals were identified for Breztri in KALOS or LOGOS. Full results from the two Phase 3 trials will be shared with regulatory authorities and presented at an upcoming medical meeting. Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan. In addition to the two registrational trials (KALOS and LOGOS), two qualifying trials, LITHOS and VATHOS, also met their primary endpoints. LITHOS and VATHOS included approximately 1,000 randomized patients. In April, Sanofi SA (NASDAQ:SNY) reported preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in heterogeneous inflammatory asthma. The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses. Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60. A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident. In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60. AstraZeneca announced in its first-quarter presentation (PDF) on Tuesday that it had stopped working on a phase 1 Alzheimer's disease drug and two phase 2 programs for migraine and osteoarthritis pain and painful diabetic neuropathy. On Tuesday, the European pharma giant reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion, driven by double-digit growth in oncology and biopharmaceuticals. Price Action: AZN stock is up 1.52% at $71.58 at the last check Friday. Read Next:Photo by Piotr Swat Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ASTRAZENECA (AZN): Free Stock Analysis Report This article AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
